Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > January 18, 2024
Daily News
January 18, 2024
- Market Expansion Re-Pricing to Hit 23 Meds in April, Opdivo Faces Yet Another Cut in Spillover
January 18, 2024
- Updated Rules OK’ed for FY2024 Reform, 5-10% Rate Set for New Premium to Counter Lag/Loss
January 18, 2024
- 9 APIs to Earn Increased Premiums in FY2024 Price Revision; Jakavi Gets Multiple Premiums
January 18, 2024
- Sawai Exits US Biz to Cope with GMP and Supply Issues in Japan
January 18, 2024
- Takeda’s Hyqvia Earns US Nod for CIDP Maintenance Therapy
January 18, 2024
- US Patent Office Nixes Seagen Patent in ADC Row: Daiichi Sankyo
January 18, 2024
- Ono Deplores Regulator’s Decision on Opdivo Spillover Re-Pricing
January 18, 2024
- Parmodia Tops November GP Rep Promotion List, Dayvigo HP Champion for 4th Month
January 18, 2024
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…